what lab tests to be done with a case of Hereditary hemochromatosis (HH) and uncontrolled idabtes
Reading File
Finding Sources
Finding Sources
Searching the Web
hereditary hemochromatosis uncontrolled diabetes lab tests investigations workup 2024
Finding Sources
Finding Sources
Reading Web Page
https://www.ncbi.nlm.nih.gov/books/NBK594250
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
I now have comprehensive information from multiple authoritative sources. Let me compile a well-organized answer.
Lab Tests for Hereditary Hemochromatosis (HH) with Uncontrolled Diabetes
This combination is clinically significant: HH causes iron deposition in the pancreas, directly damaging islet cells and causing "bronze diabetes." The workup must cover both conditions and their shared complications.
Part 1 - Hereditary Hemochromatosis Investigations
A. Initial Iron Studies (First-Line)
| Test | Abnormal Value | Significance |
|---|---|---|
| Serum Iron | Elevated | Baseline iron status |
| Total Iron Binding Capacity (TIBC) | Elevated (>450 mcg/dL) | Confirms pathological iron accumulation |
| Transferrin Saturation (TSAT) | >45% (males/non-menstruating females); >50% in males highly specific | Most sensitive early marker; LR+ 10.9 for TSAT ≥50% in men |
| Serum Ferritin | >300 µg/L (males/non-menstruating females); >200 µg/L (menstruating females) | Index of total body iron stores |
A normal ferritin + TSAT <45% has a 97% negative predictive value for iron overload (NCBI StatPearls, 2024)
B. Genetic Testing (Confirmatory)
- HFE gene mutation analysis: C282Y, H63D, and S65C mutations
- C282Y homozygosity confirms type 1 HH (the most common form)
- Compound heterozygote C282Y/H63D is also diagnostic
- Note: Non-HFE forms (types 2-4) require specialized lab testing
- Note: A 2024 Danish cohort study (BMJ 2024;387:e079147) found C282Y homozygotes have a 1.72x higher risk of diabetes and 2.22x higher risk of liver disease even when iron markers are normal
C. Liver Assessment
| Test | Purpose |
|---|---|
| Liver function tests (AST, ALT, ALP, GGT, bilirubin, albumin) | Hepatic iron injury; note - aminotransferases may be normal even in advanced fibrosis |
| Prothrombin time / INR | Synthetic liver function |
| Liver biopsy (if ferritin >1000 µg/L or age >40) | Gold standard for fibrosis staging and hepatic iron concentration |
| MRI liver (T2)* | Non-invasive quantification of hepatic iron; also evaluates pancreatic iron deposition |
| Liver elastography / FibroScan | Non-invasive fibrosis assessment |
| Alpha-fetoprotein (AFP) | Screening for hepatocellular carcinoma (~30% of cirrhotic HH patients develop HCC) |
D. Cardiac Assessment
| Test | Purpose |
|---|---|
| ECG | Conduction defects, arrhythmias (supraventricular tachyarrhythmias, heart block) |
| Echocardiogram | Diastolic dysfunction, dilated cardiomyopathy |
| Cardiac MRI (T2)* | Quantify myocardial iron deposition |
| BNP / NT-proBNP | Heart failure screening |
E. Endocrine Panel
| Test | Purpose |
|---|---|
| LH, FSH, testosterone (males) / estradiol (females) | Hypogonadism (2nd most common endocrine complication) |
| TSH, Free T4 | Hypothyroidism prevalence 80x higher in HH |
| Morning cortisol / ACTH stimulation test | Adrenal insufficiency |
| PTH and Vitamin D | Osteoporosis risk (hypogonadism + liver disease) |
| Bone mineral density (DEXA) | Osteoporosis screening |
F. Joint/Articular Investigations
- X-ray of hands (2nd/3rd MCP joints are classically first affected in HH arthropathy)
- Serum uric acid
- Synovial fluid analysis if effusion present (chondrocalcinosis is a feature)
Part 2 - Uncontrolled Diabetes Investigations
In this context, diabetes is most likely caused or worsened by pancreatic iron deposition ("bronze diabetes"). Investigations serve for diagnosis, monitoring, and complication assessment.
A. Glycemic Status
| Test | Details |
|---|---|
| Fasting plasma glucose | Target 80-130 mg/dL |
| HbA1c | Best measure of chronic glycemic control; target varies by patient |
| 2-hour OGTT (75g) | If fasting glucose borderline or OGTT pattern needed |
| Postprandial glucose | Target <180 mg/dL (2h) |
| Fasting insulin / C-peptide | Distinguishes beta cell destruction (low C-peptide in HH-diabetes) from insulin resistance |
Important caveat: HbA1c may be falsely low in HH due to iron deficiency after phlebotomy therapy or hemolysis - use fructosamine or continuous glucose monitoring as alternatives in such cases.
B. Renal Function (Diabetic Nephropathy)
| Test | Purpose |
|---|---|
| Serum creatinine + eGFR | Baseline renal function |
| BUN (Blood Urea Nitrogen) | Renal status |
| Urine microalbumin:creatinine ratio | Early nephropathy detection |
| 24-hour urine protein (if microalbuminuria positive) | Quantify proteinuria |
| Urine dipstick | Gross proteinuria, glucose, ketones |
C. Lipid Profile
- Fasting lipids: Total cholesterol, LDL, HDL, triglycerides
- Uncontrolled diabetes is associated with hypertriglyceridemia and low HDL
D. Cardiovascular Risk Panel
- Blood pressure (hypertension highly common in diabetes)
- Homocysteine (if indicated)
- hsCRP (inflammation)
E. Thyroid and Other Endocrine
- TSH (already elevated risk in HH; diabetes also associated with thyroid disease)
F. Diabetic Complication Screening
| System | Test |
|---|---|
| Eyes | Dilated fundoscopy (diabetic retinopathy) |
| Nerve | Monofilament test, nerve conduction studies (peripheral neuropathy) |
| Feet | Ankle-brachial index (peripheral arterial disease) |
Part 3 - Integrated/Overlap Investigations
These are particularly important given the dual diagnosis:
| Test | Rationale |
|---|---|
| MRI abdomen (liver + pancreas T2)* | Assess iron overload in both organs simultaneously |
| CBC with differential | Baseline for phlebotomy therapy planning |
| Serum phosphorus, calcium, magnesium | Electrolyte disturbances in both renal disease and pancreatopathy |
| Uric acid | Elevated in both HH arthropathy and metabolic syndrome |
| Hepatitis B & C serology | Exclude viral hepatitis co-contributing to liver disease |
| Serum ceruloplasmin | Exclude Wilson's disease if non-HFE iron overload |
Summary Flowchart of Priority
- Iron studies (TSAT + ferritin) → if elevated → HFE gene testing
- HbA1c + fasting glucose → glycemic status
- LFTs + liver MRI/biopsy → liver staging
- Endocrine panel → gonadal, thyroid, adrenal function
- Renal screen → microalbuminuria, eGFR
- Cardiac screen → ECG, echo
- Lipids + CV risk
Sources: Harrison's Principles of Internal Medicine 22E (2025), Goldman-Cecil Medicine 27th Ed., Henry's Clinical Diagnosis and Management by Laboratory Methods, NCBI StatPearls (Laboratory Evaluation of Hereditary Hemochromatosis, 2024), Symptom to Diagnosis 4th Ed.
This is a shared conversation. Sign in to Orris to start your own chat.